 |
| |
| Dec-03-18 | Reiterated |
H.C. Wainwright |
Buy |
$125 → $150 |
|
| Aug-06-18 | Initiated |
Piper Jaffray |
Overweight |
$80 |
|
| Jun-27-18 | Reiterated |
H.C. Wainwright |
Buy |
$73 → $125 |
|
| Jun-27-18 | Reiterated |
Cantor Fitzgerald |
Overweight |
$69 → $96 |
|
| May-08-18 | Reiterated |
SunTrust |
Buy |
$80 → $77 |
|
| Mar-21-18 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
| Feb-28-18 | Reiterated |
Cantor Fitzgerald |
Overweight |
$61 → $72 |
|
| Feb-14-18 | Initiated |
Janney |
Buy |
|
|
| Jan-23-18 | Initiated |
William Blair |
Outperform |
|
|
| Dec-14-17 | Reiterated |
Needham |
Buy |
$51 → $70 |
|
| Dec-01-17 | Initiated |
H.C. Wainwright |
Buy |
$73 |
|
| Sep-21-17 | Initiated |
Needham |
Buy |
$51 |
|
| Aug-08-17 | Reiterated |
JP Morgan |
Overweight |
$44 → $46 |
|
| Apr-18-17 | Initiated |
SunTrust |
Buy |
$56 |
|
| Mar-21-17 | Resumed |
Wedbush |
Outperform |
$73 |
|
| Mar-16-17 | Initiated |
Cantor Fitzgerald |
Overweight |
$61 |
|
| Mar-02-17 | Initiated |
Instinet |
Buy |
$50 |
|
| Jan-04-17 | Initiated |
JP Morgan |
Overweight |
|
|
| Nov-01-16 | Initiated |
ROTH Capital |
Buy |
$47 |
|
| Oct-25-16 | Reiterated |
Wedbush |
Outperform |
$66 → $73 |
|
|
|
| Dec-13-18 08:32AM | Ghost Tree Capitals AUM, Returns and Holdings Insider Monkey |
| Dec-11-18 12:05PM | Here's Why Global Blood Therapeutics Fell 10.1% in November, Then Jumped 37% Since Motley Fool |
| Dec-10-18 07:15AM | Global Blood Therapeutics, Voxelotor in Advanced Clinicals, Analysts Review and Target ACCESSWIRE |
| Dec-07-18 09:15AM | Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering GlobeNewswire -8.60% |
| 08:04AM | The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut Benzinga |
| 07:00AM | 3 Biotech Stocks That Could Explode Higher in 2019 SmarterAnalyst |
| Dec-06-18 04:05PM | Global Blood Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire |
| 01:48PM | 3 Top Stocks After #ASH18 Motley Fool |
| Dec-05-18 09:39AM | Jim Cramer Advises His Viewers On Adobe, Barnes & Noble And More Benzinga |
| Dec-04-18 06:48PM | Cramer's lightning round: Barnes & Noble's stock is trading like it could get acquired CNBC |
| 04:05PM | GBT Announces New Employment Inducement Grants GlobeNewswire |
| 09:30AM | Company News For Dec 4, 2018 Zacks |
| 09:15AM | Stocks Jump 1% on 90-Day Tariff Delay Zacks |
| 08:13AM | Global Blood Therapeutics' Voxelotor on Faster Approval Path Zacks |
| 07:00AM | Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Global Blood Therapeutics ACCESSWIRE |
| Dec-03-18 11:55AM | Global Blood's Sickle Cell Disease Drug Snags Accelerated FDA Approval Pathway Benzinga +47.81% |
| 10:37AM | Why Global Blood Therapeutics Skyrocketed Today Motley Fool |
| 10:01AM | Global Blood Therapeutics stock up 40% after FDA agrees to accelerated approval pathway for sickle cell disease drug MarketWatch |
| 10:00AM | GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile GlobeNewswire |
| 08:00AM | GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA) GlobeNewswire |
| Dec-02-18 07:00PM | GBT to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Provide a Regulatory Update for Voxelotor GlobeNewswire |
| Nov-30-18 09:15AM | The Market is All Packed for Buenos Aires Zacks |
| Nov-20-18 08:51AM | Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options Zacks |
| Nov-09-18 07:25AM | Report: Exploring Fundamental Drivers Behind California Water Service Group Holding, Canadian Solar, JELD-WEN Holding, CONSOL Coal Resources LP, Global Blood Therapeutics, and Pier 1 Imports New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
| Nov-08-18 05:34PM | Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion for a higher price American City Business Journals |
| 07:05AM | Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and Global Blood Therapeutics ACCESSWIRE |
| Nov-07-18 08:24AM | 3 Top Biotech Stocks to Buy in November Motley Fool +5.17% |
| Nov-06-18 07:13PM | Global Blood: 3Q Earnings Snapshot Associated Press |
| 04:05PM | GBT Reports Recent Business Progress and Provides Third Quarter 2018 Financial Results GlobeNewswire |
| 08:00AM | GBT Announces New Employment Inducement Grants GlobeNewswire |
| Nov-01-18 03:37PM | Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp. PR Newswire +12.31% |
| 09:00AM | GBT Announces Upcoming Data Presentations at 60th American Society of Hematology (ASH) Annual Meeting & Exposition GlobeNewswire |
| Oct-25-18 11:46AM | GUERBET : Revenue at September 30, 2018 GlobeNewswire |
| Oct-04-18 04:05PM | GBT Announces New Employment Inducement Grants GlobeNewswire |
| 08:00AM | GBT Announces Upcoming Presentations at National Sickle Cell Disease Association of America (SCDAA) Convention GlobeNewswire |
| Sep-27-18 11:11AM | SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Global Blood Therapeutics, Inc. (GBT) GlobeNewswire |
| 08:40AM | Analysis: Positioning to Benefit within CONSOL Coal Resources LP, QTS Realty Trust, MakeMyTrip, Momo, QIWI, and Global Blood Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire |
| Sep-26-18 04:05PM | GBT Announces Participation at the 2018 Cantor Global Healthcare Conference GlobeNewswire |
| Sep-25-18 12:08PM | GUERBET : 2018 half-year results GlobeNewswire |
| Sep-24-18 07:19PM | Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating Possible Securities Fraud Violations by Certain Officers and Directors of Alnylam, Global Blood, and NiSource on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire |
| Sep-18-18 08:20PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Global Blood Therapeutics, Inc. - GBT ACCESSWIRE |
| Sep-17-18 03:40PM | Oppenheimers 7 Top Stock Picks for September Kiplinger |
| 08:47AM | Are Options Traders Betting on a Big Move in Global Blood (GBT) Stock? Zacks |
| Sep-14-18 06:07PM | INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Global Blood Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire |
| 08:00AM | Today's Research Reports on Trending Tickers: Ironwood Pharmaceuticals and Global Blood Therapeutics ACCESSWIRE |
| Sep-13-18 06:16PM | EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Global Blood Therapeutics, Inc. GBT Business Wire -7.40% |
| 05:34PM | Bragar Eagel & Squire, P.C. is Investigating Global Blood Therapeutics, Inc. (GBT) on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire |
| 04:05PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Global Blood Therapeutics, Inc. - GBT PR Newswire |
| 12:33PM | SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Global Blood Therapeutics, Inc. (GBT) PR Newswire |
| Sep-12-18 06:00PM | Bluebird Bio Stock May Have Upside of at Least 60 Percent InvestorPlace |
| Sep-07-18 04:05PM | GBT Announces Participation at the 2018 Morgan Stanley Global Healthcare Conference GlobeNewswire |
| Sep-06-18 04:05PM | GBT Announces New Employment Inducement Grants GlobeNewswire -6.50% |
| 08:00AM | GBT Brings Together Sickle Cell Disease Influencers at 7th Annual Sickle Cell Disease (SCD) Therapeutics Conference GlobeNewswire |
| Sep-05-18 08:30AM | 3 Biotech Stocks Ready to Burn Up TheStreet.com |
| Aug-28-18 10:50AM | Oppenheimers 7 Top Stock Picks for September InvestorPlace |
| Aug-23-18 08:00AM | Today's Research Reports on Trending Tickers: Immunomedics and Global Blood Therapeutics ACCESSWIRE |
| 08:00AM | GBT Expands Sickle Cell Disease Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis GlobeNewswire |
| Aug-21-18 08:00AM | GBT Appoints Heidi L. Wagner as Senior Vice President, Government Affairs and Policy GlobeNewswire |
| Aug-16-18 08:00AM | Today's Research Reports on Trending Tickers: Cronos Group and Global Blood Therapeutics ACCESSWIRE |
| Aug-07-18 04:05PM | GBT Announces Participation at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire |
| Aug-03-18 04:05PM | GBT Announces New Employment Inducement Grants GlobeNewswire +6.64% |
| Aug-02-18 06:59PM | Global Blood: 2Q Earnings Snapshot Associated Press |
| 04:05PM | GBT Reports Recent Business Progress and Provides Second Quarter 2018 Financial Results GlobeNewswire |
| Jul-26-18 03:47PM | A guide to biotechs building boom in South City American City Business Journals |
| 08:20AM | Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Global Blood Therapeutics ACCESSWIRE |
| 08:00AM | Free Technical Insights on BioPharmX and Three Other Biotech Stocks ACCESSWIRE |
| Jul-04-18 08:00AM | Today's Research Reports on Trending Tickers: Clovis Oncology and Global Blood Therapeutics ACCESSWIRE |
| Jul-03-18 04:05PM | GBT Announces New Employment Inducement Grants GlobeNewswire |
| Jun-28-18 08:20AM | Global Blood Therapeutics is making a big gamble on its sickle cell drug MarketWatch +6.03% |
| 08:10AM | Today's Research Reports on Trending Tickers: Global Blood Therapeutics and Cara Therapeutics ACCESSWIRE |
| Jun-27-18 06:11PM | Why Sangamo Therapeutics and bluebird bio Slipped Lower Today Motley Fool +15.63% |
| 05:14PM | Why Global Blood Therapeutics Surged 10.7% Higher Motley Fool |
| 03:31PM | Why a $500 Million Bet on a Looser FDA Makes Sense Bloomberg |
| 11:12AM | GBT's drug meets trial goal, investors skeptical of speedy approval Reuters |
| 10:05AM | Global Blood Therapeutics Meets Primary Endpoints In Sickle Cell Study, Seeks Accelerated FDA Approval Benzinga |
| 08:35AM | Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options Zacks |
| 07:38AM | Global Blood Therapeutics' sickle cell disease drug succeeds in trial Reuters |
| 07:30AM | GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease GlobeNewswire |
| Jun-25-18 12:50PM | 3 Killer Stocks Trading at Unfair Discounts TheStreet.com -7.02% |
| Jun-15-18 01:06PM | Here's Why Shares of Global Blood Therapeutics Inc Are Falling Today Motley Fool -14.88% |
| 11:33AM | Global Blood Therapeutics Shares Plunge After Sickle Cell Candidate Shows Reduced Effect Benzinga |
| 02:30AM | GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European Hematology Association (EHA) Congress GlobeNewswire |
| Jun-14-18 07:05AM | Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities ACCESSWIRE |
| Jun-13-18 02:55PM | Hematology Conference Could Spur Some of Biotech's Outperformers Bloomberg |
| Jun-08-18 08:30AM | GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease (SCD) Program at Foundation for Sickle Cell Disease Researchs 12th Annual Symposium GlobeNewswire |
| Jun-05-18 04:05PM | GBT Announces New Employment Inducement Grants GlobeNewswire |
| Jun-04-18 07:35AM | Consolidated Research: 2018 Summary Expectations for ManTech International, Rapid7, Global Blood Therapeutics, CONSOL Coal Resources LP, Ryanair, and Yandex N.V. Fundamental Analysis, Key Performance Indications GlobeNewswire |
| May-25-18 08:40AM | Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options Zacks |
| May-23-18 03:00AM | Stocks To Watch: Global Blood Therapeutic Sees RS Rating Jump To 83 Investor's Business Daily |
| May-19-18 10:00AM | Even Momentum Traders Should Study Stock Charts TheStreet.com |
| May-18-18 07:31PM | Global Blood Therapeutics Incs (NASDAQ:GBT) Profit Outlook Simply Wall St. |
| May-17-18 10:30AM | GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European Hematology Association (EHA) Congress GlobeNewswire |
| May-11-18 12:25PM | Having Some Good Luck With Biotech Names TheStreet.com +5.66% |
| May-09-18 01:52PM | Markets Make an Art of Unpredictability TheStreet.com |
| May-08-18 12:03PM | Markets Confused by Trump's Upcoming Iran Decision TheStreet.com +7.96% |
| May-07-18 04:58PM | Global Blood: 1Q Earnings Snapshot Associated Press |
| 04:05PM | GBT Reports Recent Business Progress and First Quarter 2018 Financial Results GlobeNewswire |
| May-04-18 08:30AM | GBT Announces New Employment Inducement Grants GlobeNewswire |
| Apr-27-18 07:30AM | [$$] Biotechs Make Headway in Battle Against Sickle Cell Disease The Wall Street Journal |
| Apr-10-18 07:35AM | Factors of Influence in 2018, Key Indicators and Opportunity within Global Blood Therapeutics, Wix, Changyou, BT Group, Golar LNG, and NantHealth New Research Emphasizes Economic Growth GlobeNewswire +7.65% |
|
|
|
|
| Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Farrow Jeffrey S | Chief Financial Officer | Nov 27 | Option Exercise | 16.40 | 3,048 | 49,987 | 15,555 | Nov 28 06:01 PM | | Calhoun Lesley Ann | See Remarks | Aug 17 | Sale | 49.19 | 300 | 14,756 | 838 | Aug 20 08:25 PM | | Calhoun Lesley Ann | See Remarks | Aug 16 | Option Exercise | 22.00 | 1,500 | 33,000 | 2,638 | Aug 20 08:25 PM | | Calhoun Lesley Ann | See Remarks | Aug 16 | Sale | 50.01 | 1,704 | 85,214 | 1,138 | Aug 20 08:25 PM | | LOVE TED W | See Remarks | Jul 16 | Option Exercise | 16.40 | 12,194 | 199,982 | 1,117,979 | Jul 17 09:30 PM | | Calhoun Lesley Ann | See Remarks | Jul 09 | Option Exercise | 22.00 | 2,295 | 50,490 | 2,683 | Jul 10 06:10 PM | | Calhoun Lesley Ann | See Remarks | Jul 09 | Sale | 44.27 | 2,295 | 101,609 | 388 | Jul 10 06:10 PM | | Calhoun Lesley Ann | See Remarks | Jul 06 | Option Exercise | 22.00 | 1,000 | 22,000 | 1,388 | Jul 10 06:10 PM | | PATRICK DEVAL L | Director | Jul 06 | Option Exercise | 21.42 | 42,379 | 907,631 | 42,379 | Jul 10 06:13 PM | | PATRICK DEVAL L | Director | Jul 06 | Sale | 43.40 | 42,379 | 1,839,283 | 0 | Jul 10 06:13 PM | | Calhoun Lesley Ann | See Remarks | Jul 06 | Sale | 44.01 | 1,000 | 44,005 | 388 | Jul 10 06:10 PM | | Choi Jung | See Remarks | May 17 | Option Exercise | 3.40 | 1,400 | 4,760 | 137,477 | May 21 04:36 PM | | Choi Jung | See Remarks | May 17 | Sale | 48.25 | 3,000 | 144,750 | 136,077 | May 21 04:36 PM | | Choi Jung | See Remarks | Apr 17 | Option Exercise | 3.40 | 1,400 | 4,760 | 139,077 | Apr 19 04:05 PM | | Choi Jung | See Remarks | Apr 17 | Sale | 45.50 | 3,000 | 136,500 | 137,677 | Apr 19 04:05 PM | | Choi Jung | See Remarks | Mar 16 | Option Exercise | 3.40 | 1,400 | 4,760 | 140,677 | Mar 20 05:30 PM | | Choi Jung | See Remarks | Mar 16 | Sale | 54.15 | 3,000 | 162,450 | 139,277 | Mar 20 05:30 PM | | Sham Hing | See Remarks | Mar 07 | Option Exercise | 0.49 | 10,714 | 5,250 | 98,215 | Mar 09 05:30 PM | | Calhoun Lesley Ann | See Remarks | Mar 05 | Sale | 60.35 | 99 | 5,975 | 388 | Mar 05 05:00 PM | | Choi Jung | See Remarks | Feb 16 | Option Exercise | 3.40 | 1,400 | 4,760 | 142,277 | Feb 21 06:10 PM | | Choi Jung | See Remarks | Feb 16 | Sale | 62.95 | 3,000 | 188,850 | 140,877 | Feb 21 06:10 PM | | Radovich Peter | See Remarks | Feb 01 | Sale | 57.30 | 812 | 46,528 | 6,817 | Feb 02 08:17 PM | | Radovich Peter | See Remarks | Jan 23 | Option Exercise | 1.61 | 30,000 | 48,300 | 33,581 | Jan 25 08:09 PM | | Radovich Peter | See Remarks | Jan 23 | Sale | 60.00 | 30,000 | 1,800,000 | 3,581 | Jan 25 08:09 PM | | Choi Jung | See Remarks | Jan 17 | Option Exercise | 3.40 | 1,400 | 4,760 | 137,778 | Jan 18 07:59 PM | | Choi Jung | See Remarks | Jan 17 | Sale | 52.85 | 3,000 | 158,550 | 134,778 | Jan 18 07:59 PM | | Radovich Peter | See Remarks | Jan 10 | Option Exercise | 1.61 | 15,000 | 24,150 | 17,684 | Jan 11 09:48 PM | | Radovich Peter | See Remarks | Jan 10 | Sale | 50.00 | 15,000 | 750,000 | 2,684 | Jan 11 09:48 PM | | PERCEPTIVE ADVISORS LLC | 10% Owner | Dec 19 | Buy | 38.00 | 175,000 | 6,650,000 | 4,889,066 | Dec 19 08:22 PM |
|
|
|
|
|
|
